17696-95-6

Basic information

• Product Name: NSC82194
• Synonyms: NSC82194;HydrazinecarboxaMide, N-Methyl-;N-MethylhydrazinecarboxaMide;1-AMino-3-Methylurea
• CAS NO: 17696-95-6
• Molecular Formula: C₂H₇N₃O
• Molecular Weight: 89.09648
• Mol File: 17696-95-6.mol
• Article Data: 8

Chemical Properties

• Melting Point: 112 °C
• Appearance: /
• Density: 1.114g/cm³
• Refractive Index: 1.464
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 12.29±0.20(Predicted)
• CAS DataBase Reference: NSC82194(CAS DataBase Reference)
• NIST Chemistry Reference: NSC82194(17696-95-6)
• EPA Substance Registry System: NSC82194(17696-95-6)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• Hazardous Substances Data: 17696-95-6(Hazardous Substances Data)

Usage

Description

NSC82194, also known as N-Methylhydrazinecarboxamide, is a chemical compound with potential applications in various fields. It is characterized by its unique molecular structure, which allows it to interact with specific biological targets and modulate their activity.

Uses

Used in Pharmaceutical Industry:
NSC82194 is used as a precursor in the preparation of heteroarylalkylene aryl sultam derivatives, which serve as RORc modulators. RORc (Retinoid-related Orphan Receptor C) is a nuclear receptor that plays a crucial role in various biological processes, including immune response and inflammation. Modulating RORc activity can have therapeutic implications in treating autoimmune diseases, inflammatory disorders, and other conditions related to the immune system.

InChI:InChI=1/C2H7N3O/c1-4-2(6)5-3/h3H2,1H3,(H2,4,5,6)

Upstream product

• 624-83-9 methyl isocyanate 
• 7647-01-0 hydrogenchloride 
• 1943-79-9 N-Methyl-O-phenylcarbamat 
• 13912-48-6 N-methyl-N'-nitrourea 
• 7664-93-9 sulfuric acid 
• 6610-29-3 4-methylthiosemicarbazide 
• 10309-97-4 pyrocatechol monomethylcarbamate 
• 13256-32-1 1,3 dimethyl 1 nitrosourea 

Downstream Products

• 40848-87-1 1-benzylidene-4-methylsemicarbazide 
• 16813-41-5 1-(2-Chloroethyl)-6-methylbiurea 
• 3190-35-0 4-Methyl-semicarbazid-1,1-bis-(carbimidsaeure-2,4-dimethyl-phenylester) 
• 1456-21-9 diphenyl-[1,3,4]thiadiazole 
• 109142-12-3 4-methyl-1-thiobenzoylsemicarbazide 
• 116114-19-3 4-fluoro-N-[(methylcarbamoyl)amino]benzamide 
• 1352808-70-8 ethyl (1E)-2-(3,4-dichlorophenyl)-2-hydroxy-N-(methylcarbamoyl)propanehydrazonoate 
• 1352808-96-8 ethyl (1Z)-2-(3,4-dichlorophenyl)-2-hydroxy-N-(methylcarbamoyl)propanehydrazonoate 
• 1231766-71-4 C₁₀H₁₃N₃O₃ 
• 1231766-73-6 C₁₀H₁₃N₃O₂ 
• 215458-73-4 4-(4-fluorophenoxy)benzaldehyde 4'-methylsemicarbazone 
• 874974-93-3 C₁₉H₁₇F₃N₄O₃ 
• 623907-63-1 benzoic acid, 4-iodo-2-[(methylamino)carbonyl]hydrazide 
• 287378-95-4 C₁₉H₂₀N₄O₆ 

Relevant articles and documents

Experimental studies of spatial patterns produced by diffusion-convection-reaction systems

The reactions between chlorite ions and a series of sulfur compounds are bistable and autocatalytic in hypochlorous acid. Unstirred solution mixtures of chlorite ions and thiourea, for example, can generate a travelling wave of chemical reactivity at the surface from a point of initial perturbation These reactions are highly exothermic and exhibit a sharp temperature jump at the wave front (ΔT ≈ 3-5°C). In stoichiometric excess of chlorite ions and in unstirred solutions the travelling wave is followed by spatial patterns in the bulk of the solution. The spatial patterns, which show areas of varying acid concentrations, can be sustained for up to 15 min. Formation of the travelling wave is due to thermocapillary effects. The transition to patterns is fuelled by the coupling of buoyancy forces with thermocapillary convection.

Highly efficient synthesis of hiv nnrti doravirine

The development of an efficient and robust process for the production of HIV NNRTI doravirine is described. The synthesis features a continuous aldol reaction as part of a de novo synthesis of the key pyridone fragment. Conditions for the continuous flow aldol reaction were derived using microbatch snapshots of the flow process.

HETEROCYCLIC HYDRAZONE COMPOUNDS AND THEIR USES TO TREAT CANCER AND INFLAMMATION

The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).